Zamoner Welder, de Freitas Fernanda M, Garms Durval S S, de Oliveira Mariele Gobo, Balbi André L, Ponce Daniela
Nephrology University São Paulo State-UNESP Botucatu SP 18618-970 Brazil.
Pharmacol Res Perspect. 2016 Nov 24;4(6):e00280. doi: 10.1002/prp2.280. eCollection 2016 Dec.
Sepsis is the most common cause of death in critically ill patients and is associated with multiorgan failure, including acute kidney injury (AKI). This situation can require acute renal support and increase mortality. Therefore, it is essential to administer antimicrobials in doses that achieve adequate serum levels, avoiding both overdosing and drug toxicity as well as underdosing and the risk of antibiotic resistance and higher mortality. Currently, there are no validated guidelines on antibiotic dose adjustments in septic patients with AKI. The current recommendations were extrapolated from studies conducted in noncritical patients with end-stage chronic kidney disease receiving chronic renal replacement therapy. This study aimed to review and discuss the complexity of this issue, considering several factors related to drug metabolism, the characteristics of critically ill patients, the properties of antimicrobial drugs and dialysis methods.
脓毒症是危重症患者最常见的死亡原因,与多器官功能衰竭相关,包括急性肾损伤(AKI)。这种情况可能需要急性肾脏支持并增加死亡率。因此,给予能达到足够血清水平的抗菌药物剂量至关重要,要避免用药过量和药物毒性以及用药不足和抗生素耐药风险及更高死亡率。目前,对于合并AKI的脓毒症患者,尚无经过验证的抗生素剂量调整指南。当前的建议是从对接受慢性肾脏替代治疗的终末期慢性肾病非危重症患者进行的研究中推断出来的。本研究旨在回顾和讨论该问题的复杂性,考虑与药物代谢、危重症患者特征、抗菌药物特性及透析方法相关的几个因素。